linjc16/ctgov huggingface dataset:
Reliability and Cross-cultural Adaptation of the Turkish Version of the Neuropathic Pain Symptom Inventory

Study Overview
=================
Brief Summary
-----------------
In this study, investigators want to perform the reliability and cross-cultural Adaptation of the Turkish Version of the Neuropathic Pain Symptom Inventory

Detailed Description
-----------------
The purpose of the study is to determine the Turkish version, the reliability and cross-cultural Adaptation of the Turkish Version of the Neuropathic Pain Symptom Inventory. 120 patients with neuropathic pain will be included in the study. Test-retest and internal consistency analysis were conducted to determine the reliability of the questionnaire. Test-retest results evaluated using the Intraclass Correlation Coefficient method.

Official Title
-----------------
Reliability and Cross-cultural Adaptation of the Turkish Version of the Neuropathic Pain Symptom Inventory

Conditions
-----------------
Neuropathic Pain

Intervention / Treatment
-----------------
* Other: Neuropathic Pain Symptom Inventory


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age upper 18 Complaints of neuropathic pain for at least 3 months Exclusion Criteria: Presence of psychiatric illness Cancer pain, unsuccessful lumbar surgeon syndrome etc. mix type pain presence Presence of complex regional pain syndrome Cognitive impairment (mini-mental test score <24) Native language is not Turkish

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Neuropathic Pain Symptom Inventory|Investigators will use the Neuropathic Pain Symptom Inventory for assessing neuropathic symptoms|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reliability and adaptation | Investigators will use linguistic validaiton guideline of Mapi research. | 7 weeks | 
| DN4 | DN4 has become one of the principal condition-specific outcome measures of neuropathic pain.Investigators will use it for comparing results of NPSI. | 5 minutes |
An Observational Study of Japanese Participants With X-linked Retinitis Pigmentosa

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to identify a cohort of Japanese participants with X-linked retinitis pigmentosa (XLRP) associated with pathogenic variants in the retinitis pigmentosa GTPase regulator (RPGR) gene and to investigate their associated phenotype.

Official Title
-----------------
Prospective Observational Study to Estimate the Genotype and Phenotype of Japanese Patients With X-linked Retinitis Pigmentosa Associated With Pathogenic Variants in Retinitis Pigmentosa GTPase Regulator (RPGR)

Conditions
-----------------
X-Linked Retinitis Pigmentosa

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Have RPGR-associated retinal dystrophy Are able to give informed consent or assent, with the guidance of their parent/guardian where appropriate Are able to undertake age-appropriate clinical assessments as specified in the protocol Exclusion Criteria: Are unable or unwilling to undertake consent or clinical testing Participated in another research study and had intraocular surgery within 3 months of screening Significant ophthalmologic diseases

Ages Eligible for Study
-----------------
Minimum Age: 5 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Participants with X-Linked Retinitis Pigmentosa (XLRP)<br>Participants with confirmed diagnosis of XLRP associated with pathogenic variants in retinitis pigmentosa GTPase regulator (RPGR) in the Japanese population will be enrolled in the study and the data will be collected and observed. The primary data source for this study will be the medical records of each participant. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual Function | Visual function will be assessed using visual acuity. | Up to Day 30 | 
| Retinal Structure | Retinal structure will be assessed using spectral domain optical coherence tomography (SDOCT). | Up to Day 30 | 
| Retinal Function | Retinal function will be assessed using static visual field testing. | Up to Day 30 |
Topical Timolol for the Treatment of Benign Vascular Periocular Lesions

Study Overview
=================
Brief Summary
-----------------
The purpose of this research is to find out if the use of topical timolol 0.5% solution applied twice daily will help to shrink rosacea lesions around the eye.

Detailed Description
-----------------
Benign vascular tumors of the eyelid are common causes of ocular morbidity. Capillary hemangiomas in children cause refractive and occlusive amblyopia. In adults, Rosacea-associated eyelid telangiectasis and sclerosis can result in keratitis and corneal neovascularization. Corticosteroid therapy of benign vascular lesions risks sight-threatening complications including central retinal artery occlusion and significant systemic morbidity. Alternatively, oral and intravenous beta-blockers have been reported to induce regression of benign vascular lesions. One recent report documented efficacy of topical timolol in treating a large capillary hemangioma of the eyelid in a child. Topical application reduces systemic side effects of beta-blockers including bradycardia, hypotension, heart block, and bronchospasm. This one-year prospective case-control series will investigate whether topical Timolol 0.5% solution applied twice daily causes significant regression of benign vascular periocular lesions.

Official Title
-----------------
Topical Timolol for the Treatment of Benign Vascular Periocular Lesions

Conditions
-----------------
Benign Vascular Periocular Lesions

Intervention / Treatment
-----------------
* Drug: topical Timolol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Presence of a benign vascular periocular lesion Exclusion Criteria: Allergy to timolol or beta-blocker class of drugs Lesion characteristics concerning for atypia or malignancy including madarosis, ulceration, and recurrence after previous surgery. Intraocular Pressure less than 10 mm Hg

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Topical timolol<br>topical Timolol 0.5% solution applied twice daily | Drug: topical Timolol<br>* topical Timolol 0.5% solution applied twice daily<br>* Other names: Timoptic;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| lesion resolution | Pre-treatment and post-treatment lesion size will then be compared to determine whether twice-daily topical application of timolol 0.5% solution alters the morphometry of benign vascular periocular lesions. | 1 year |
Sensitivity and Specificity of Aridol Challenge for a Diagnosis of Asthma by a Specialist Pulmonologist

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to estimate the sensitivity, specificity and positive and negative predictive values of a positive Aridol challenge with respect to a specialist pulmonologist diagnosis of asthma in corticosteroid naive subjects with asthma-like symptoms and no previous diagnosis of asthma. The comparator is methacholine provocation

Official Title
-----------------
Sensitivity and Specificity of Aridol Challenge for a Diagnosis of Asthma by a Specialist Pulmonologist

Conditions
-----------------
Asthma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Informed consent Provisional or possible asthma diagnosis FEV1 at least 70% of predicted at inclusion Exclusion Criteria: Contraindications for bronchial provocation challenge or spirometry Respiratory tract infection within previous 6 weeks Significant co-morbidity > 10 pack year smoking history Other lung diseases Pregnancy, lactation

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| sensitivity, specificity and positive and negative predictive values of a positive Aridol bronchial challenge test | with respect to asthma diagnosis by a specialist pulmonary physician in corticosteroid-naïve subjects presenting with signs and symptoms suggestive of asthma but without a definitive diagnosis. | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
asthma, airway hyperresponsiveness, dry powder mannitol inhalation, methacholine
Local GIT Hormones After Bariatric Maneuvers

Study Overview
=================
Brief Summary
-----------------
Background: Many of the beneficial metabolic effects of bariatric surgery have been attributed to altered peptide hormone profiles, especially involving pancreatic and gut peptides. Objectives: assess the effects of bariatric procedures (sleeve gastrectomy, minigastric bypass and sleeve gastrectomy with loop bipartition) on GIT hormones. Methods: Prospective randomized study which was carried out in the department of General Surgery, Minia University hospital during the period from February 2018 to February 2019. This study included 3 groups subjected to different operations; each group consisted of 50 patients.

Detailed Description
-----------------
Prospective randomized study which was carried out in the department of General Surgery, Minia University hospital during the period from February 2018 to February 2019. This study included 3 groups subjected to different operations; each group consisted of 50 patients. Age ranging from 20 to 50 years old and body weight ranging from 100 to 200 Kg, and subjected to laparoscopic sleeve gastrectomy, mini gastric bypass and sleeve gastrectomy with loop bipartition. Each patient was thoroughly evaluated by a multidisciplinary team (Nutritionist, Endocrinologist, Psychologist, and Surgeon) using a standardized protocol. Follow up was done after two weeks and after 2 months.

Official Title
-----------------
Effect of Bariatric Surgery

Conditions
-----------------
Morbid Obesity

Intervention / Treatment
-----------------
* Procedure: sleeve gastrectomy with loop bipartition


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All morbid obese patients - Exclusion Criteria: GIT diseases
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: surgeries
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: laparoscopic sleeve gastrectomy<br> | Procedure: sleeve gastrectomy with loop bipartition<br>* operations to decrease weight<br>* Other names: minigastric bypass;|
| Active Comparator: mini gastric bypass<br> | Procedure: sleeve gastrectomy with loop bipartition<br>* operations to decrease weight<br>* Other names: minigastric bypass;|
| Active Comparator: sleeve gastrectomy with loop bipartition<br> | Procedure: sleeve gastrectomy with loop bipartition<br>* operations to decrease weight<br>* Other names: minigastric bypass;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| hormonal change | GIT hormones (Ghrelin, secretin, PYY, GLP-1) | one year |
MIld to MOderate Acute Pancreatitis: Early naSogastric Tube Feeding Compared With pAncreas Rest (MIMOSA)

Study Overview
=================
Brief Summary
-----------------
Pain relapse during oral refeeding occurs in at least one-fifth of patients with acute pancreatitis. The study hypothesis is that early administered enteral tube feeding might reduce a risk of pain relapse and shorten the length of hospital stay in patients with acute pancreatitis.

Official Title
-----------------
Early Enteral Tube Feeding Compared With Pancreas Rest in Patients With Acute Pancreatitis: a Randomized Controlled Trial

Conditions
-----------------
Acute Pancreatitis

Intervention / Treatment
-----------------
* Procedure: Enteral tube feeding


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diagnosis of acute pancreatitis age 18 years or older written informed consent Exclusion Criteria: > 96 hours after onset of symptoms > 24 hours after hospital admission organ failure by the time of randomization infectious complications before randomization received artificial nutrition before randomization previously enrolled into the trial chronic pancreatitis post-ERCP pancreatitis intraoperative diagnosis of acute pancreatitis pregnancy malignancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Enteral tube feeding<br>Nasogastric tube feeding started within 24 h of hospital admission | Procedure: Enteral tube feeding<br>* Nasogastric tube feeding started within 24 h of hospital admission<br>|
| No Intervention: Nil-per-mouth regimen<br>Conventional management | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Length of hospital stay |  | Up to 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain relapse |  | Up to 3 months | 
| Local and systemic complications |  | Up to 3 months | 
| Feeding intolerance |  | Up to 3 months | 
| Time to solid oral food tolerated |  | Approx. one week | 
| Pain-free time |  | Up to 3 months | 
| Hospital readmission |  | Up to 6 months | 
| Quality of life |  | Up to 6 months | 
| Mortality |  | Up to 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Acute pancreatitis, Enteral nutrition, Pancreas rest
Consequences of Hypoglycemia on Intensive Care Unit (ICU) Patients

Study Overview
=================
Brief Summary
-----------------
Hypoglycemia occurs frequently during intensive blood glucose control in critically ill patients. The incidence of hypoglycaemia is associated with impaired outcome. However, it is hitherto unknown if hypoglycaemia itself predisposes patients to neurological impairment, e.g. cognitive dysfunction, or if it is the underlying medical condition that makes the patient prone to a high risk of hypoglycaemia and, concomitantly, neurocognitive impairment. Therefore we investigate neurocognitive function in patients who had hypoglycemias during their intensive care stay and compare the results to patients without hypoglycaemia whose medical conditions are matched to the hypoglycaemia patients.

Official Title
-----------------
Does Hypoglycemia Under Intensive Insulin Therapy During Critical Illness Lead to Neurocognitive Dysfunction

Conditions
-----------------
Critical Illness

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all patients Exclusion Criteria: clinical diagnosis of diabetes mellitus brain injury of any kind prior to or upon ICU-admission pre-existing mental or psychiatric disorder terminal kidney or liver failure prior admission drug abuse, CPR > 5 min HIV Lues

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>patients with hypoglycemia during intensive care | |
| 2<br>patients without hypoglycemia during intensive care | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| neurocognitive function |  | 1 year after ICU discharge | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| neurocognitive function |  | 2,3, and 4 years after ICU discharge | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
critical illness, hypoglycemia, neurocognitive dysfunction, intensive insulin therapy
The Use of X-ray in Bariatric Surgeries

Study Overview
=================
Brief Summary
-----------------
examination of the importance of the use of X-ray in bariatric surgery outcome.

Detailed Description
-----------------
the x-ray will be used in order to evaluate the number of complications occured during bariatric surgeries such as bleeding, leak, etc. a retrospective analysis of patients with those complications will be performed and the presence of the x-ray and its findings will also be documented.

Official Title
-----------------
The Use of X-ray in Bariatric Surgeries

Conditions
-----------------
Complications of Bariatric Procedures, X-rays; Effects

Intervention / Treatment
-----------------
* Device: x-ray


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: first bariatric surgery Exclusion Criteria: recurrent bariatric surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| with x-ray<br>patients underwent bariatric surgery and underwent x-ray | Device: x-ray<br>* x-ray for the detection of leaks and bleeding<br>|
| without x-ray<br>patients underwent bariatric surgery and did not underwent x-ray | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| complications | the outcome measure will be assessed and data will be presented in six months | retrospective- data collection and analysis will be ended in six months. |
Comparing the Effects of Two Beta Blockers,Metoprolol and Nebivolol,on Ambulatory Blood Pressure and Basal Metabolic Rate

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to compare the effects of nebivolol and metoprolol on 24-hour ambulatory blood pressure characteristics and basal metabolic rates in patients with hypertension.

Official Title
-----------------
Comparative Effects of Nebivolol Versus Metoprolol on 24-hour Blood Pressures and Basal Metabolic Rate: An Open-Label Study

Conditions
-----------------
Hypertension

Intervention / Treatment
-----------------
* Drug: Metoprolol
* Drug: Nebivolol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years old or older currently be treated at a University of MS Medical Center Internal Medicine Clinics currently taking metoprolol succinate for hypertension have their hypertension controlled (<140/90). Exclusion Criteria: uncontrolled hypertension severe renal or moderate hepatic impairment currently taking CYP 2D6 inducers/inhibitors recent stroke (less than 6 months) recent myocardial infarction (less than 6 months) congestive heart failure diagnosed obstructive sleep apnea atrial fibrillation arm circumference >50 cm

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Metoprolol to nebivolol<br>metoprolol 25-200mg at a stable daily dose for 4 weeks, then change to nebivolol at a comparable stable dose (5-20 mg) for 4 -5 weeks. | Drug: Metoprolol<br>* Metoprolol tablets 25-200 mg daily times four weeks. Nebivolol daily for 4-5 weeks<br>* Other names: Metoprolol is lopressor;Drug: Nebivolol<br>* 5 - 20 mg daily, at a stable dose for 4 to 5 weeks<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Primary Outcome is Pre- and Post-treatment Ambulatory Blood Pressure. |  | 4 weeks (pre- and post-treatment) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hypertension, Beta-blockers, Ambulatory blood pressure, Basal metabolic rate, Quality of life